Study: NCT03274297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.